Search Results535 results found
Why CSL Behring’s Diane McCabe has organ donation in her thoughts at work and at home.
CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology
CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients
The company's dedication to addressing the community's needs is one of the reasons why I choose to partner with CSL Behring."
CSL Behring, Leader in Rare Diseases, Hosts a Symposium on CIDP, Presents 7 Poster Sessions Featuring PATH Study Data at the 15th International Congress on Neuromuscular Diseases
CSL Behring hosts symposium featuring patient perspective on subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment
CSL Behring is a global biotech company leading the way to deliver innovative therapies for rare and serious diseases.
Read CSL Behring's news releases from 2019.
Here’s why thousands of biotech leaders flock to the global meetup
Leading industry publication ranks top global biotechnology regions.
A year-long lab assignment helps a young researcher find her path